N-(叔-丁基)-N-甲基甲酰胺 | 63957-05-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(叔-丁基)-N-甲基甲酰胺
• 英文名称: N-methyl-N-tert-butylformamide
• 英文别名: N-tert-butyl-N-methylformamide；N-t-Butyl-N-methylformamid；N-Methyl-N-tert.-butyl-formamid；FORMAMIDE, N-(tert-BUTYL)-N-METHYL-
• CAS: 63957-05-1
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: GZKMWSAXNHPVJH-UHFFFAOYSA-N

物化性质

• 沸点：
  80-82 °C(Press: 15 Torr)
• 密度：
  0.871±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  N-(叔-丁基)-N-甲基甲酰胺 在 硫酸 作用下， 生成 N-甲基-叔丁基胺
  参考文献：
  名称：

  Phase-Transfer-CatalysedN-Alkylation ofN-Substituted Formamides; An Alternative Procedure for the Ritter Reaction

  摘要：

  DOI：

  10.1055/s-1979-28759
• 作为产物：
  描述：

  N-甲基-叔丁基胺 、 二氧化碳 在 二苯基硅烷 、 C₂₁H₄₁N₃NiP₂ 作用下， 以 乙腈 为溶剂， 20.0 ℃ 、830.92 kPa 条件下， 反应 24.0h， 以96%的产率得到N-(叔-丁基)-N-甲基甲酰胺
  参考文献：
  名称：

  脱芳构的PN 3 P *-氢化镍夹钳复合物对CO 2还原的不同催化活性†

  摘要：

  使用氧化加成法制备了脱芳香化的PN 3 P *-氢化镍配合物。首次实现了镍催化的CO 2加氢硅烷化为甲醇，其转化率空前。此类PN 3 P *-氢化镍氢化物证明了胺与CO 2的选择性甲基化和甲酰化，突出了其在CO 2还原中的多功能性。

  DOI：

  10.1039/c8cc05948a

文献信息

• SUBSTITUTED BIPIPERIDINYL DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318866A1

  公开（公告）日：2016-11-03

  The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  该发明涉及新型取代的双哌啶衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、外周和心脏血管疾病、血栓栓塞疾病和缺血、外周循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及外周和自主神经病变的治疗和/或预防。
• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• [EN] SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1 TRICYCLIQUES SPIRO FUSIONNÉS
  申请人：BAYER AG

  公开号：WO2021074279A1

  公开（公告）日：2021-04-22

  The present invention relates to Map4K1 inhibitors of formula (I) to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的Map4K1抑制剂，以及包含根据本发明的化合物的药物组合物和组合物，以及创新化合物的预防性和治疗性用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病，癌症或与异常MAP4K1信号相关的其他紊乱免疫反应或其他紊乱的疾病，作为单一药剂或与其他活性成分组合使用。本发明还涉及使用，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物的用途。
• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF
  申请人：Brüggemeier Ulf

  公开号：US20100261771A1

  公开（公告）日：2010-10-14

  The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新的、取代的2-乙酰胺基-5-芳基-1,2,4-三唑酮，以及制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。